Thymopentin

Summary

Thymopentin (CHEMBL156025) is a phase-3 clinical-stage protein (ATC L03AX09); indicated across 3 conditions including hepatocellular carcinoma and hiv infectious disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Protein
• ATC class: L03AX09
• Indications: 3 conditions
• Clinical trials: 9
• Chemistry: 679.8 Da · C30H49N9O9

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL156025
Name	Thymopentin
Type	Protein
Max phase	3
FDA approved	no
PubChem CID	451417
ATC	L03AX09
Molecular formula	C30H49N9O9
Molecular weight	679.8
InChIKey	PSWFFKRAVBDQEG-YGQNSOCVSA-N

SMILES: CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)N

IUPAC name: (3S)-3-[[(2S)-6-amino-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-4-[[(2S)-1-[[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid

Also known as: Arg-lys-asp-val-tyr, Hg-thymopentin, Immunox, NSC-760116, ORF 15244, ORF-15244, Oristar thymopentin, Pentapeptide-1, Sh-pentapeptide-1, Sintomodulina, Thymopentin, Thymopentine

Patent coverage: 3,787 distinct patent families (12,507 SureChEMBL compound mentions), from 2 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: 5-hydroxytryptamine receptor 2C.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
hepatocellular carcinoma	3	MONDO:0007256	EFO:0000182
HIV infectious disease	3	MONDO:0005109	EFO:0000764
neoplasm	3	MONDO:0005070	EFO:0000616

Clinical trials

Total trials: 9.

Phase distribution

Phase	Trials
Not specified	5
PHASE3	2
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00002109	PHASE3	COMPLETED	Double-Blind Study of Timunox (Thymopentin) in Asymptomatic HIV-Infected Patients Receiving Either Mono (AZT or ddI) or Combination (AZT / ddI or AZT / ddC) Anti-Retroviral Therapy
NCT00460681	PHASE3	UNKNOWN	Study of Thymopentin in Patients After Curative Resection of Small Hepatocellular Carcinoma
NCT06112041	PHASE2	NOT_YET_RECRUITING	The Prospective Clinical Study of Precision PRaG Therapy in Elderly Patients With Advanced Solid Malignant Tumors (PRaG9.0)
NCT00002332	PHASE2	COMPLETED	A Study of Timunox (Thymopentin) in HIV-Infected Patients Receiving Other Anti-HIV Drugs
NCT00002049	Not specified	COMPLETED	Double Blind Study of Thymopentin Effects on HIV-1 Infectivity of Blood Mononuclear Cells and Semen in HIV Infected Patients
NCT00002050	Not specified	COMPLETED	A Study of Thymopentin Effects on HIV-1 Infectivity of Blood Mononuclear Cells and Semen in HIV Infected Patients
NCT00002051	Not specified	COMPLETED	Double Blind Study of Thymopentin Effects on Patients With HIV-1 Infection
NCT00002066	Not specified	COMPLETED	Double Blind Study of Thymopentin Effects on Patients With HIV-1 Infection
NCT00002289	Not specified	COMPLETED	The Effects of Thymopentin on HIV Infectivity of Blood Cells and Semen in HIV-Infected Patients

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).